• Evofem Biosciences posted net loss of $5.5 million for quarter ended March 31, 2026, swinging from net income of $1 million a year earlier.
• Net product sales rose 6% to $899,000, reflecting higher WAC for PHEXX and stronger SOLOSEC demand, partly offset by lower PHEXX volume following heavy wholesaler buying in December ahead of a January price increase.
• Total other expense widened to $897,000 from other income of $629,000, driven by $700,000 of interest expense tied mainly to Adjuvant Note and $200,000 loss on fair-value changes in financial instruments.
• Cash and cash equivalents totaled $2.4 million at March 31, including $900,000 of restricted cash, while working capital deficit stood at $72.7 million and management said existing liquidity is insufficient to fund operations for at least the next 12 months.
• April updates included a fourth amendment extending Adjuvant Notes maturity to earlier of six months after April 10, 2026 or a change of control, and an exclusive five-year distributorship deal with Clovis Davis to commercialize SOLOSEC in sub-Saharan Africa starting April 24.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023928), on May 15, 2026, and is solely responsible for the information contained therein.